Infant Formula Lipid Mixture with sn-2 Palmitic Acid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current infant formulas fail to accurately replicate the unique triglyceride and phospholipid composition of human breast milk, which is crucial for the mental and physical development of infants, leading to potential nutritional deficiencies and developmental issues.
Innovation Solution
A composition comprising at least one triglyceride, one phospholipid, and one long-chain poly-unsaturated fatty acid (LC-PUFA), with specific formulations of these components to mimic the structure and benefits of human milk fat, including conjugation of LC-PUFAs to triglycerides and phospholipids, to enhance nutritional efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional infant formulas use standard vegetable oil blends to provide fatty acids, then the formulas can be manufactured easily and cost-effectively, but they fail to replicate the unique sn-2 palmitic acid structure and phospholipid composition of human breast milk, leading to suboptimal nutritional outcomes
Solution Approach 1:
The patent changes the chemical structure parameters of triglycerides by ensuring palmitic acid is positioned specifically at the sn-2 position rather than being randomly distributed. This structural parameter change replicates human breast milk composition while maintaining manufacturability through established interesterification or enzymatic processes.
Solution Approach 2:
The patent creates a composite lipid structure combining specific triglycerides with sn-2 palmitic acid and phospholipids in defined ratios. This composite approach replicates the complexity of human milk fat while providing a manufacturable formulation that addresses both nutritional requirements and production feasibility.
2Reliability
If infant formulas include adequate amounts of long-chain polyunsaturated fatty acids (LC-PUFAs) for brain development, then cognitive development is improved, but the absorption and utilization efficiency decreases when LC-PUFAs are not properly conjugated to phospholipids
Solution Approach 1:
The patent applies local quality by specifically conjugating LC-PUFAs to phospholipid molecules at defined positions, creating localized high-value nutritional structures. This ensures optimal absorption and utilization in the infant intestine while maintaining overall formula simplicity and manufacturability.
Solution Approach 2:
Phospholipids serve as intermediary carriers that bind LC-PUFAs in specific configurations. This intermediary structure enhances the bioavailability and absorption of LC-PUFAs in the infant gastrointestinal tract, improving nutritional efficacy without requiring complex formulation approaches.
3Quantity of substance
If formulas use phospholipids from soybean sources to improve cognitive function, then choline content and membrane composition are enhanced, but the overall lipid structure fails to mimic human breast milk phospholipid profiles
Solution Approach 1:
The patent changes the compositional parameters of phospholipids by specifying not only the quantity but also the fatty acid distribution patterns and head group composition to match human breast milk profiles. This ensures compositional consistency and stability while maintaining the cognitive development benefits.
Solution Approach 2:
The patent applies homogeneity by ensuring uniform distribution and consistent composition of phospholipid species throughout the formula. This creates a stable, reproducible product that reliably delivers the intended nutritional benefits for brain development and membrane composition.
Data Source
AI summary
The subject invention thus provides a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said at least one phospholipid and uses thereof.